UniCycive Therapeutics Inc (UNCY)

[Whalatane]

RMB The ARDX move is IMHO all about IBSRELA .....they doubled their estimate of peak sales for that drug / indication from $500m to $1Billion.
They aren't using Xphozah at the dialysis clinics my wife rounds at yet. She says the main issue is problems with insurance coverage for her medicare / medicaid patients . Remember Co wants close to $3,000 a mth for the drug so patients would have a copay of close to $1,000 as I believe they can't use company coupons .
Her patients can't afford that copay.

UNCY ...yes the drug is a bioequivalent to Fosrenol ...a lanthanum carbonate my wife does prescribe.
Issue with the existing drug is the size of the pill , taste as it has to be chewed , and cost vs Sevelamer
UNCY's drug OLC is a far smaller pill , swallowed not chewed with meals ...cost yet to be determined.

Being able to swallow one small pill with meals is seen as a big advantage re patient adherence.
An advantage for the prescribers such as my wife is that its considered almost the same ( but in improved form ) of a drug she already prescribes .

Challenges going forward .
They have to complete final trial with dialysis patients ...mid / late 2024 ...with an acceptable safety profile
After that ...overcome any patent challenges .
My time horizon currently is just to trial results ...will reassess then

Hedge funds definitely piling in given the vol we are seeing
JMO

Kiwi